SRPK3 exacerbates cardiac ischemia/reperfusion injury by regulating KLF3-mTOR/P70 S6K-mediated autophagy

Yun Xing1,2, Sai-Yang Xie1,2, Nan Zhao1,2

  • 1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.

Insights

Serine/arginine-Rich Protein Kinase 3 (SRPK3) exacerbates myocardial ischemia-reperfusion (I/R) injury by inducing lethal autophagy through the KLF3-mTOR pathway. Inhibiting SRPK3 may offer a therapeutic strategy for ischemic heart disease.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Cellular Stress Response

Background:

  • Myocardial ischemia-reperfusion (I/R) injury is a major cause of heart failure and mortality.
  • The precise role of Serine/arginine-Rich Protein Kinase 3 (SRPK3) in cardiac I/R injury is not well understood.

Purpose of the Study:

  • To investigate the pathological role of SRPK3 in myocardial I/R injury.
  • To elucidate the molecular mechanisms by which SRPK3 influences cardiac dysfunction during I/R.

Main Methods:

  • Cardiac-specific SRPK3 knockout mouse models and cardiomyocyte hypoxia/reoxygenation assays were employed.
  • Transcriptomics, phosphoproteomics, and site-directed mutagenesis were integrated to identify molecular interactions.
  • Analysis of cardiac function, infarct size, apoptosis, oxidative stress, and autophagic flux was performed.

Main Results:

  • SRPK3 deficiency protected cardiac function, reduced infarct size, and attenuated apoptosis and oxidative stress post-I/R.
  • SRPK3 overexpression worsened I/R injury phenotypes.
  • SRPK3 was found to directly phosphorylate Transcription Factor KLF3 at Ser71, inhibiting mTOR signaling and promoting excessive, pathological autophagy.

Conclusions:

  • SRPK3 acts as a detrimental regulator in myocardial I/R injury by inducing lethal autophagy via the KLF3-mTOR axis.
  • The SRPK3-KLF3 interaction represents a critical molecular switch in I/R injury.
  • Targeting the SRPK3-KLF3 pathway offers a potential therapeutic avenue for ischemic heart disease.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...